The aim was to review available literature on capecitabine-based chemoradiation regimens
for the preoperative treatment of patients with locally advanced rectal cancer (LARC) and …

Background: Traditionally, metastatic colorectal cancer (MCRC) has been treated with
intravenous (iv) 5-fluorouracil/leucovorin (5-FU/LV). The tumour-activated, oral …

Background In the UK, about 26% of patients diagnosed with colorectal cancer are classified
as Stage III (Dukes' C) at presentation. These patients have an overall 5-year survival rate of …

Background: Capecitabine results in superior response rate, improved safety, and improved
convenience compared with 5-fluorouracil (FU)/leucovorin (LV) in metastatic colorectal …

OAKLEY C., JOHNSON J. & REAM E.(2010) European Journal of Cancer Care19, 21–28
Developing an intervention for cancer patients prescribed oral chemotherapy: a generic …

Abstract For more than 40 years, 5-fluorouracil (5-FU) has been considered the most
effective systemic agent for managing advanced colorectal cancer. However, continuous …

Fluoropyrimidine chemotherapy, principally with 5-fluorouracil (5-FU), has been a standard
of care for a range of solid tumours for many years. Capecitabine, a precursor of 5-FU, is an …

Breast and colon cancer occur primarily in people over the age of 65 years, yet standards of
care are mostly derived from clinical trials conducted with predominantly younger patients …

Home-based therapy with oral capecitabine (Xeloda®) has a number of advantages over iv
hospital-based chemotherapy regimens, including improvement in patients' quality of life …

Purpose This study evaluated the effects of oral capecitabine on the quality of life (QOL) of
Brazilian patients with metastatic colorectal cancer who received capecitabine (1000 or …